AIT Therapeutics Announces Completion of the Agreement to License the Revolutionary Nitric Oxide Generator and Delivery System

AIT Therapeutics (OTC:AITB), a clinical-stage biopharmaceutical company focused on developing inhaled Nitric Oxide for the treatment of patients with serious lung infections and pulmonary hypertension, announced it has entered into an agreement acquiring a global, exclusive, transferable license to the eNOGenerator and associated critical assets including intellectual property, know-how, trade secrets and confidential information from NitricGen.

As quoted in the press release:

“This system has the potential to be transformative for the delivery of NO in any setting, and we have already completed the vast majority of our commercial manufacturing process,” stated Steve Lisi, chairman and chief executive officer of AIT Therapeutics.  “We anticipate patients and caregivers will benefit from the use of our revolutionary system in 2019 for primary pulmonary hypertension in neonates (PPHN) in 2019, bronchiolitis in 2020 and nontuberculous mycobacteria (NTM) infections of the lung in 2021.”

Click here to read the full press release.